3SBio In-licenses Second Anti-Cancer mAb from Korea's PharmAbcine

China's 3SBio signed a second deal to in-license a cancer drug candidate from PharmAbcine of Korea, this time for a bi-specific antibody. DIG-KT, which has an anti-angiogenesis mechanism, targets both the VEGFR2/KDR and Tie-2 pathways. Two months ago, 3SBio in-licensed rights to a PharmAbcine mAb with only the VEGFR2/KDR target. 3SBio will have rights in Greater China and Korea to the latest drug. The agreement includes upfront, milestone and royalty payments, though specific amounts were not disclosed. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.